Janux Therapeutics (JANX) News Today $23.45 -0.95 (-3.89%) Closing price 09/19/2025 04:00 PM EasternExtended Trading$23.94 +0.50 (+2.11%) As of 09/19/2025 06:31 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock JANX Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 Time Period Janux Therapeutics (NASDAQ:JANX) Raised to Strong-Buy at BarclaysSeptember 19 at 6:47 AM | marketbeat.comJanux Therapeutics (NASDAQ:JANX) Shares Gap Up - Here's WhySeptember 18 at 12:34 PM | marketbeat.comJanux Therapeutics (NASDAQ:JANX) Now Covered by BarclaysSeptember 18 at 8:14 AM | marketbeat.comJanux Therapeutics (NASDAQ:JANX) Now Covered by Analysts at BarclaysSeptember 18 at 3:11 AM | americanbankingnews.comBarclays Initiates Coverage of Janux Therapeutics (JANX) with Overweight RecommendationSeptember 17 at 5:04 PM | msn.comJanux Therapeutics initiated with an Overweight at BarclaysSeptember 16, 2025 | msn.comGoldman Sachs Group Inc. Has $7.73 Million Stock Holdings in Janux Therapeutics, Inc. $JANXSeptember 16, 2025 | marketbeat.comTruist Initiates Coverage on Janux Therapeutics (JANX) with a Buy Rating, $100 PTSeptember 15, 2025 | msn.comFinancial Survey: Werewolf Therapeutics (NASDAQ:HOWL) & Janux Therapeutics (NASDAQ:JANX)September 13, 2025 | americanbankingnews.comJanux Therapeutics (NASDAQ:JANX) Now Covered by Truist FinancialSeptember 12, 2025 | marketbeat.comStifel Nicolaus Reaffirms Buy Rating for Janux Therapeutics (NASDAQ:JANX)September 12, 2025 | marketbeat.comWoodline Partners LP Sells 395,092 Shares of Janux Therapeutics, Inc. $JANXSeptember 12, 2025 | marketbeat.comJanux Therapeutics' (JANX) "Buy" Rating Reiterated at Stifel NicolausSeptember 12, 2025 | americanbankingnews.comJanux Therapeutics initiated with a Buy at TruistSeptember 11, 2025 | msn.comTruist Securities Initiates Coverage of Janux Therapeutics (JANX) with Buy RecommendationSeptember 11, 2025 | msn.comJanux Therapeutics resumed with a Buy at StifelSeptember 10, 2025 | msn.comJanux is a new Buy at Truist ahead of catalyst rich H2September 10, 2025 | msn.comCubist Systematic Strategies LLC Buys 35,511 Shares of Janux Therapeutics, Inc. $JANXSeptember 9, 2025 | marketbeat.comJanux Therapeutics (NASDAQ:JANX) Now Covered by GuggenheimSeptember 8, 2025 | marketbeat.comAlyeska Investment Group L.P. Acquires 63,762 Shares of Janux Therapeutics, Inc. $JANXSeptember 7, 2025 | marketbeat.comWalleye Capital LLC Invests $307,000 in Janux Therapeutics, Inc. $JANXSeptember 6, 2025 | marketbeat.comJanux Therapeutics, Inc. (NASDAQ:JANX) Given Consensus Recommendation of "Buy" by BrokeragesSeptember 6, 2025 | marketbeat.comJanux Therapeutics, Inc. $JANX Shares Purchased by Adage Capital Partners GP L.L.C.September 5, 2025 | marketbeat.comGuggenheim Initiates Coverage of Janux Therapeutics (JANX) with Buy RecommendationSeptember 5, 2025 | msn.comFirst Light Asset Management LLC Purchases 345,042 Shares of Janux Therapeutics, Inc. $JANXSeptember 4, 2025 | marketbeat.comMPM Bioimpact LLC Has $15.31 Million Position in Janux Therapeutics, Inc. $JANXSeptember 4, 2025 | marketbeat.comJanux Therapeutics, Inc. $JANX Stock Position Increased by RA Capital Management L.P.September 4, 2025 | marketbeat.comJanux Therapeutics initiated with a Buy at GuggenheimSeptember 4, 2025 | msn.comTrexquant Investment LP Grows Stake in Janux Therapeutics, Inc. $JANXSeptember 3, 2025 | marketbeat.comJanux Therapeutics, Inc. $JANX Stake Trimmed by Paradigm Biocapital Advisors LPSeptember 2, 2025 | marketbeat.comMagnetar Financial LLC Purchases 27,557 Shares of Janux Therapeutics, Inc. $JANXSeptember 2, 2025 | marketbeat.comTema Etfs LLC Raises Stake in Janux Therapeutics, Inc. $JANXAugust 30, 2025 | marketbeat.comPrice T Rowe Associates Inc. MD Has $37.61 Million Holdings in Janux Therapeutics, Inc. $JANXAugust 30, 2025 | marketbeat.comWellington Management Group LLP Cuts Position in Janux Therapeutics, Inc. $JANXAugust 30, 2025 | marketbeat.comNuveen LLC Makes New Investment in Janux Therapeutics, Inc. $JANXAugust 30, 2025 | marketbeat.comJump Financial LLC Takes Position in Janux Therapeutics, Inc. $JANXAugust 29, 2025 | marketbeat.comJanux Therapeutics, Inc. $JANX Stock Holdings Cut by Invesco Ltd.August 29, 2025 | marketbeat.comBTIG Reaffirms Their Buy Rating on Janux Therapeutics Inc (JANX)August 27, 2025 | theglobeandmail.comVanguard Group Inc. Has $61.52 Million Stock Holdings in Janux Therapeutics, Inc. $JANXAugust 26, 2025 | marketbeat.comAlgert Global LLC Reduces Stock Position in Janux Therapeutics, Inc. $JANXAugust 25, 2025 | marketbeat.comRussell Investments Group Ltd. Purchases 152,837 Shares of Janux Therapeutics, Inc. $JANXAugust 25, 2025 | marketbeat.comErste Asset Management GmbH Invests $786,000 in Janux Therapeutics, Inc. $JANXAugust 24, 2025 | marketbeat.comJanux Therapeutics, Inc. $JANX Shares Purchased by Aberdeen Group plcAugust 23, 2025 | marketbeat.comPiper Sandler Initiates Coverage of Janux Therapeutics (JANX) with Overweight RecommendationAugust 20, 2025 | msn.comJanux Therapeutics initiated with an Overweight at Piper SandlerAugust 19, 2025 | msn.comPiper starts Janux Therapeutics with an Overweight on ‘best-in-class’ potentialAugust 19, 2025 | msn.comJanux Therapeutics, Inc. (NASDAQ:JANX) Shares Sold by Lord Abbett & CO. LLCAugust 18, 2025 | marketbeat.comQ3 EPS Estimate for Janux Therapeutics Reduced by AnalystAugust 16, 2025 | marketbeat.comHC Wainwright Expects Higher Earnings for Janux TherapeuticsAugust 14, 2025 | marketbeat.comHC Wainwright Has Bearish Estimate for JANX FY2029 EarningsAugust 13, 2025 | marketbeat.com Get Janux Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for JANX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. JANX Media Mentions By Week JANX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. JANX News Sentiment▼0.290.78▲Average Medical News Sentiment JANX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. JANX Articles This Week▼106▲JANX Articles Average Week Get the Latest News and Ratings for JANX and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Janux Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies RNA News Today MRUS News Today CRSP News Today TGTX News Today PTCT News Today MENS News Today ACLX News Today PCVX News Today KRYS News Today ARWR News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:JANX) was last updated on 9/20/2025 by MarketBeat.com Staff From Our PartnersForget NVDA. Put $1,000 into this stock nowA massive money shift is underway in the AI market. And it's opening up an extraordinary opportunity in a NEW ...Chaikin Analytics | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredWhy silver could go 100X higherInflation is destroying purchasing power at 10–14% per year. Gold will protect you — but not the way you think...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Janux Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Janux Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.